NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00012051,Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00012051,,COMPLETED,"RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Peripheral stem cell transplant may be able to replace immune cells that were destroyed by the chemotherapy. Monoclonal antibodies, such as rituximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known if giving more than one drug (combination chemotherapy) plus peripheral stem cell transplant is more effective with or without monoclonal antibody therapy in treating non-Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is studying how well chemotherapy plus peripheral stem cell transplant with or without monoclonal antibody therapy works in treating patients with relapsed non-Hodgkin's lymphoma.",NO,Lymphoma,BIOLOGICAL: filgrastim|BIOLOGICAL: rituximab|DRUG: carmustine|DRUG: cisplatin|DRUG: cytarabine|DRUG: dexamethasone|DRUG: etoposide|DRUG: ifosfamide|DRUG: melphalan|DRUG: methotrexate|PROCEDURE: bone marrow ablation with stem cell support|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: radiation therapy,Overall survival,Response rate|Event-free survival,,Commissie Voor Klinisch Toegepast Onderzoek,,ALL,"ADULT, OLDER_ADULT",PHASE3,340,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: TREATMENT,CKTO-2000-06|CDR0000068476|HOVON-44|HOVON-44/CKVO-2000-06|EU-20042|ISRCTN95614846,2000-09,,2007-10,2003-01-27,,2013-08-12,"U.Z. Gasthuisberg, Leuven, B-3000, Belgium|HagaZiekenhuis - Locatie Leyenburg, 's-Gravenhage, 2545 CH, Netherlands|Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, 5211 NL, Netherlands|Meander Medisch Centrum, Amersfoort, 3816 CP, Netherlands|Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, 1066 BE, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, 1081HV, Netherlands|Academisch Medisch Centrum at University of Amsterdam, Amsterdam, 1105 AZ, Netherlands|Medisch Spectrum Twente, Enschede, 7500 KA, Netherlands|University Medical Center Groningen, Groningen, 9713 EZ, Netherlands|Medisch Centrum Leeuwarden - Zuid, Leeuwarden, 8934 AD, Netherlands|Leiden University Medical Center, Leiden, 2300 CA, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, 6202 AZ, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, 3435 CM, Netherlands|Universitair Medisch Centrum St. Radboud - Nijmegen, Nijmegen, NL-6500 HB, Netherlands|Daniel Den Hoed Cancer Center at Erasmus Medical Center, Rotterdam, 3008 AE, Netherlands|University Medical Center Utrecht, Utrecht, 3584 CX, Netherlands|Isala Klinieken - locatie Sophia, Zwolle, 8000 GK, Netherlands",
